EL7.AI
StocksMediumUpdated•Originally published 30 September 2026•Updated 30 September 2026•
1 min read

Study Shows Continued Weight Loss After Switching to Oral Wegovy Pills

Key Facts

1Real-world data showed patients switching from Wegovy or Zepbound injections to Wegovy pills continued to lose weight.
2Patients who stayed on the pill treatment for three months lost roughly 4% of their weight on average.

Real-world data showed patients switching from Wegovy or Zepbound injections to Wegovy pills continued to lose weight. CNBC reported that patients who stayed on the pill treatment for three months lost roughly 4% of their weight on average, highlighting the efficacy of the oral format in a non-clinical setting.

LLY closed at $1184.63 on September 29, 2026, as the market evaluates the transition toward more convenient oral administrations in the high-growth obesity drug category. The stock reached a day high of $1192.94 and a low of $1168.47 during that session.

Latest Updates · 1

  1. Notable·

    Update: Experimental data showed a Regeneron drug reduced muscle mass loss by 50% when used in combination with Novo Nordisk's semaglutide compared to semaglutide alone. These clinical findings address a key side effect of leading obesity treatments by focusing on the quality of weight loss through muscle preservation.